Shire on high after drug approval

Shire, the pharmaceutical company, will launch a new treatment for patients suffering from Gaucher disease.

The product, named VPRIV, was granted marketing approval by the US Food and Drug Administration yesterday.

The VPRIV application has also been granted accelerated assessment by the European Union. Shire expects to launch VPRIV in the EU by the end of 2010.